SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as shareholders react to a significant seven billion dollar equity and equity-linked financing announcement intended to fund a massive backlog of new AI server orders. While the community is debating whether this move is a necessary step to scale production for record demand or an aggressive dilution that signals deeper issues, traders are focused on the stock's high volatility and the potential for a long-term growth play.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors debate the impact of shifting geopolitical tensions with Iran and the company's decision to cancel a planned spinoff of its media assets. Community discussion is polarized, with some users highlighting the risks of international conflict and others focusing on the simplified corporate structure and the long-term potential of the merger.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors debate the sustainability of AI infrastructure spending and its impact on the company's capital intensity ahead of its upcoming earnings report. The community remains heavily divided, with many traders closely watching for signs of institutional accumulation or potential shifts in AI revenue durability to justify high-end price targets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors react to positive Phase 1 data for subcutaneous Briumvi in myasthenia gravis and the initiation of a registration-directed Phase 2 trial. The community remains focused on buyout speculation and the drug's potential to capture broader market share through simplified dosing regimens.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as the removal of pattern day trading restrictions and the launch of in-house World Cup prediction markets drive significant retail activity and volume. Investors are also closely tracking internal confidence following substantial insider buying and anticipation around upcoming major IPO accessibility on the platform.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors debate the impact of the company's recent earnings report and guidance against a backdrop of ongoing short-interest speculation and broader consumer spending concerns. While some community members remain focused on the stock's long-term potential and the stability of its Autoship revenue model, others are expressing frustration over persistent price declines and the company's performance relative to the wider market.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 ETF is experiencing heightened volatility as investors weigh sticky inflation data and geopolitical tensions in the Middle East against hopes for a potential market rotation. Market participants remain sharply divided, with intense debate centering on whether recent price movements are signs of a sustainable bull market or a temporary liquidity trap fueled by speculation.

Cracker Barrel Old Country Store, Inc. engages in the operation and development of restaurant and retail outlets. The format of its stores consists of a trademarked rustic old country-store design that offers restaurant menu featuring home-style country food. The company was founded by Dan W. Evins on September 19, 1969 and is headquartered in Lebanon, TN.

Cracker Barrel Old Country Store Inc

Cracker Barrel is trending due to a significant earnings miss and lowered guidance, which has fueled intense community debate over the company's turnaround efforts and leadership. The stock's heavy short interest and low float have created a volatile environment, with retail investors actively debating whether the current price represents a deep-value opportunity or a long-term decline.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is facing downward pressure as investors rotate capital into larger technology stocks and react to broader market volatility. Despite the recent sell-off, the community remains focused on upcoming M&A activity and critical late-stage trial data as primary catalysts for potential sector recovery.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors weigh strong momentum in the company's prediction markets and upcoming catalysts like the FIFA World Cup against ongoing concerns regarding management's share activity and stagnant price performance. The community is actively debating whether these new prediction products represent significant, additive growth or a risky distraction, while many remain focused on the stock's long-term potential as a dominant player in a rapidly evolving sports betting and wagering landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ADPT 

🚨🚨🚨

Adaptive Biotechnologies reported strong first quarter 2026 results driven by its Minimal Residual Disease (MRD) business. 

Revenue was $70.9 million, up 35% from the prior-year quarter, with MRD revenue of $67.1 million, a 53% increase. 

Immune Medicine revenue was $3.8 million, down 57%, reflecting lower Genentech-related activity.

Net loss improved to $20.0 million from $29.8 million, and Adjusted EBITDA loss narrowed to $2.5 million from $12.7 million. 

The company ended March 31, 2026 with $237.2 million in cash, cash equivalents and marketable securities and raised full-year 2026 MRD revenue guidance to $260–$270 million, implying 22–27% annual growth.

StockTwits for iOS

Adaptive Biotechnologies Corp

 

🚨🚨🚨

Adaptive Biotechnologies reported strong first quarter 2026 results driven by its Minimal Residual Disease (MRD) business. 

Revenue was $70.9 million, up 35% from the prior-year quarter, with MRD revenue of $67.1 million, a 53% increase. 

Immune Medicine revenue was $3.8 million, down 57%, reflecting lower Genentech-related activity.

Net loss improved to $20.0 million from $29.8 million, and Adjusted EBITDA loss narrowed to $2.5 million from $12.7 million. 

The company ended March 31, 2026 with $237.2 million in cash, cash equivalents and marketable securities and raised full-year 2026 MRD revenue guidance to $260–$270 million, implying 22–27% annual growth.